Tauvid Generic Name & Formulations
Legal Class
Rx
General Description
Flortaucipir F 18 [300–1900MBq/mL (8.1–51mCi/mL) at End of Synthesis (EOS)]; soln for IV inj.
Pharmacological Class
Radioactive diagnostic agent.
How Supplied
Multi-dose vials (30mL, 50mL)—1
Manufacturer
Generic Availability
NO
Mechanism of Action
Flortaucipir F 18 binds to aggregated tau protein. In the brains of patients with AD, tau aggregates combine to form NFTs, one of two components required for the neuropathological diagnosis of AD.
Tauvid Indications
Indications
For PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adults with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).
Limitations of Use
Not for evaluation of chronic traumatic encephalopathy.
Tauvid Dosage and Administration
Adult
See full labeling. Give 370MBq (10mCi) as an IV bolus dose in a total volume of ≤10mL, then follow with a NaCl 0.9% IV flush. Starting approx. 80mins after IV inj, acquire a 20-min PET image. The radiation absorbed dose from 370MBq (10mCi) dose is estimated to be 8.7mSv (weighing 70kg).
Children
Not established.
Tauvid Contraindications
Not Applicable
Tauvid Boxed Warnings
Not Applicable
Tauvid Warnings/Precautions
Warnings/Precautions
Risk of radiation exposure. Should only be used by trained and experienced personnel. Handle with appropriate safety measures to minimize radiation exposure. Risk of misdiagnosis. Consider additional evaluation to confirm the absence of AD pathology in those with a negative scan. Pregnancy: assess status in females of reproductive potential prior to initiation. Nursing mothers: avoid for 4hrs after administration.
Tauvid Pharmacokinetics
Elimination
Hepatobiliary, renal.
Tauvid Interactions
Not Applicable
Tauvid Adverse Reactions
Adverse Reactions
Headache, inj site pain, increased BP.
Tauvid Clinical Trials
See Literature
Tauvid Note
Not Applicable
Tauvid Patient Counseling
See Literature